Early Tirofiban After Thrombolysis Improves Function in Non-Cardiogenic Stroke, Safety Unresolved
This meta-analysis pools two recent randomized trials of early tirofiban after intravenous thrombolysis, giving pharmacists a consolidated efficacy and bleeding estimate for a practice that current guidelines still restrict.
📅 Journal publication: 2026(online Oct 20, 2026)·Last updated: Nov 6, 2026
Early tirofiban may enhance recovery after non-cardiogenic stroke.
This study evaluates the safety and efficacy of early antiplatelet therapy (APT) after intravenous thrombolysis in non-cardiogenic ischemic stroke. Early tirofiban improved functional outcomes (OR 1.78) without a significant rise in symptomatic intracranial hemorrhage (OR 1.19) or mortality. Findings suggest reconsidering guideline restrictions for early APT, especially with tirofiban, though the evidence is limited and further research is needed. Early tirofiban improves outcomes in non-cardiogenic stroke post-thrombolysis, warranting guideline review.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Huang Z, Chen M, Pu K
Citation:Huang Z, Chen M, Pu K Early antiplatelet therapy after intravenous thrombolysis in acute non-cardiogenic ischemic stroke: a systematic review and meta-analysis. Frontiers in neurology. 2026;17:1862583. doi:10.3389/fneur.2026.1862583